When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.

Slides:



Advertisements
Similar presentations
A Review of Codevelopment and Companion Dx Policy Elizabeth Mansfield, PhD Director, Personalized Medicine Staff OIR/CDRH/FDA NCCS Cancer Policy Roundtable.
Advertisements

The Radioactive Drug Research Committee Approval Process for Tracer Use Anthony F. Shields, M.D., Ph.D. Karmanos Cancer Institute Wayne State University.
What is involved? What are your responsibilities? May 2013: Research Institute, Clinical Research Administration Investigational New Drug Application (IND)
Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
Expanded Access Programs for Drugs and Biologics _________________________________________________________ Richard Klein Office of Health and Constituent.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
CUMC IRB Investigator Meeting Special IND/IDE Considerations: Emergency Use of Investigational Product Compassionate Use & Emergency Research July 21,
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
Special Topics in IND Regulation
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Sponsor Investigator Responsibilities under an IND
Educate fund connect support MIAP – Introduction to INDs and IDEs E Mitchell Seymour, PhD RAC Research Faculty Regulatory Project Manager.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Investigational New Drug Application 21 CFR Part 312 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Stages of drug development
Device Research Presented by Marian Serge, R.N.. Goals Identify devices Recognize difference between significant risk (SR) and non- significant risk (NSR)
Overview of the Clinical Trial & Protocol Jane Fendl March 31, 2010
February 2008 William Petros, Pharm.D., FCCP
Special Issues in FDA-Regulated Studies: The Good, the Bad, and the Ugly C. Karen Jeans, MSN, CCRN, CIP COACH Program Analyst VA Office of Research & Development.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
THE UNIVERSITY OF NEW MEXICO ▪ HEALTH SCIENCES CENTER Clinical and Translational Science Center (CTSC) 4/2009.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Jasper Ogwal-Okeng Gulu University Research Workshop 3 rd -6 th March 08.
Carine M. Lenders, M.D., M.S. Medical Director, NFL program Director, Pediatric Nutrition Support Services Research Staff, General Pediatrics Assistant.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
Investigational New Drug Application (IND)
Medical Devices IRB Determination IRB Member Continuing Education.
INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance August 22, 2003.
CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Changes to the Therapeutic Goods Act and its implications Prepared by: Anna Frazer Prosthetist Hunter Prosthetics & Orthotics Service 10 th November 2006.
Dietary Supplements. Definition by DSHEA Product that is to supplement a healthy diet. Includes ingredients such as vitamins, minerals, herbs, botanicals,
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Investigational Devices and Humanitarian Use Devices June 2007.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
HUD and Emergent Use Walter Kraft. Device Classification Significant risk – Often involve an invasive procedure for implantation or use – Requires IDE.
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
Drug Development and IND Process GC 690 Walter Kraft, MD.
CLINICAL TRIALS – PHASE IV. PHASE IV  Phase IV are post marketing studies and provide basis for continued marketing. They may also provide information.
Off Label Use in Managed Care Pharmacy Presentation Developed for the Academy of Managed Care Pharmacy Updated February 2015.
1 IND Applications for Academic Clinical Investigations John Marler, MD US Food and Drug Administration New Hampshire Avenue White Oak, MD
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.
Clinical Trials.
Presented by: Karen Jeans Program Analyst, COACH Marian Serge Program Analyst, COACH FDA Regulations: Investigational Drugs and Devices.
PD233: Design of Biomedical Devices and Systems (Lecture 2) Dr. Manish Arora CPDM, IISc Course Website:
FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.
CLINICAL INVESTIGATOR How do I put together an IND application?
Executive Director, Registrar Corp
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
Guidance for review of studies involving HCT/Ps and IND Basics
How to Put Together an IDE Application
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Device Review Decision Tree Version Date: 4/28/15 This decision tree to be used for studies involving research on a device ( approved or unapproved)
Clinical Investigations
Streamlining IRB Procedures for Expanded Access
Intermediate-Size Patient Populations INDs: What Are They, When Should They Be Used, and Who May Apply for Them?” Richard Klein, Former Director, FDA.
Opening an IND: Investigator Perspective
Presentation transcript:

When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without and IND Procedural Draft for Public Comment October 2010

Investigational New Drug – New? The FDA uses the filing requirements of the IND as the primary mechanisms for ensuring the safety of research subjects. The term IND can be misinterpreted, leading researchers to conclude that if the drug they are studying is already approved by the FDA, it is not a “new” drug needing a IND. INCORRECT! The FDA approves a drug as safe with specifications (these indications are spelled out in the Investigational Brochure, labeling, package insert or in the PDR): Route of administration Dose/duration Form of the drug (e.g. capsule vs. tablet) For specific medical conditions With concomitant medications or medical conditions

Research Studies that Require and IND Involve a drugdrug The research is a clinical investigationclinical investigation The clinical investigation is not otherwise exempt

What is a drug? “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease….” and articles (other than food) intended to affect the structure or any function of the body of man or other animals” Includes: Biologics, compounds administered to healthy subjects to blunt or provoke a physiologic response (vasopressin) or to study the mechanism of action or metabolism of a drug (contrast agents, markers). Dietary Supplements that affect the structure or function of the body and not intended for a therapeutic purpose is not a drug.

But …Off-label use is legal…… “In contrast, use of a licensed drug in the course of medical practice involves the use in an individual patient where the primary intent is to treat the patient but not to study the safety or effectiveness of a drug is any systematic way.”

Categories Exempt from IND Requirements Otherwise exempt categories There are 3: 1.Certain Research Involving Marketed Drug Products 2.Bioavailablity or Bioequivalence Studies in Humans 3.Radioactive Drugs for Certain uses

Exempt from IND Clinical investigation of a drug is exempt if all of the following criteria are met: –The Drug is licensed and marketed in US –No intent to report to FDA in support of a new indication or any other significant change in the product labeling –The investigation is not intended to support a significant change in the advertising for the (licensed) drug

Exempt from IND –The investigation does not involve a change in the route of administration, dose, population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the drug product.

Exempt from IND –The investigation is conducted in compliance with the requirements for review by an IRB (informed consent) –The investigation is conducted in compliance with the requirements of 312.7(i.e., is not intended to promote or commercialize the drug )

Changes to route, population, dosage “ not intended to require that a drug be used in exactly the same dosage form, level, and patient population described in the marketed labeling….but only permit changes…. that do not increase the risk to greater than the risk presented by the use of the product in conformance with its marketed label.”

Introducing risk - clarification Low risk modifications : blinding a product by changing its color, scoring or capsule size… Greater risk modifications; Products that are sensitive to conditions in the environment, may create changes to formulation…. or primary packaging. (examples)examples No comprehensive guide - may request consultation with FDA (formal or informal)

Introducing risk - clarification Risk assessment of a marketed drug: Oncology setting has been separated out: IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer

Consider PI sponsors may have no intent utilize study results for changing labeling or advertising but the research results may have the potential to do so….

Example changing the form Example: Coumadin® is very unstable in high humidity, which is why the pills are coated. Crushing of these caplets can change them chemically and result in unanticipated safety risks and a lack of efficacy..

Example of Manufacturing change The packaging of some drugs is very important to preserve its chemical composition. Some drugs are in blister packs, because they decompose when they come in contact with air, dark brown glass bottle if photosensitive The IUD was produced and marketed in an insertion kit which was removed and being inserted with a ring forceps. Does this introduce a design control (GMP) risk?

Lessons Learned Charging for investigational products under an IND Old rule- rarely permitted, required FDA written permission New rule November 2009 – covers charging for investigational drugs in clinical trials and expanded access use. (FDA has not changed it’s letters to reflect this change) Take home message – PI/ sponsor/ investigator researching an approved drug for unapproved use can have subject obtain drug and bill third party.

IND Decision Support tool by the University of Penn ml

Investigator/Sponsor Responsibilities MMC HRPP Web Site: rpp&catLevel=subCat

What is a Clinical Investigation? CFR 312.3(b) “,,,[an] experiment in which a drug is administered or dispensed to, or used involving, one or more human subject.” “For the purposes of [the IND regs] an experiment is, any use of a drug [approved or not] except for the use of a marketed drug in the course of medical practice.”